630P Debio 0123 + carboplatin (CP) for patients (pts) with advanced solid tumors: Safety, preliminary efficacy and determination of recommended phase II dose (RP2D)
Gelderblom, H., Saavedra Santa Gadea, O., Jalving, M., Desar, I., Gietema, J.A., Oberoi, A., Van Herpen, C., Kroep, J.R., Frederiksen Franzen, R., Bellon, A., Micallef, S., Tat, T., Dozio, V., Luong, N., Rodrigo Imedio, E.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
1813TiP Debio 0123, a highly selective WEE1 inhibitor, combined with carboplatin (CP) and etoposide (ETOP) in patients (pts) with small cell lung cancer (SCLC) that progressed after platinum-based therapy: A phase I dose escalation and expansion study
Gambardella, V., Navarro Mendivil, A.F., Lopez-Picazo Gonzalez, J.M., Jain, P., Fernandez-Hinojal, G., De Miguel, M., Zugazagoitia, J., Gadgeel, S., Bhatti, S.A., Vilalta, A., Castanon Alvarez, E., Simoes da Rocha, P.F., Micallef, S., Frederiksen Franzen, R., Piggott, L., Bellon, A., Rodrigo Imedio, E., Paz-Ares, L.G.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article